Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus

Abstract

Spanish

French

OBJECTIVE:

To review the clinical pharmacology data regarding the sulfonylurea glimepiride, and to summarize the clinical trials of glimepiride efficacy and safety alone and in combination with insulin for the treatment of type 2 diabetes mellitus.

DATA SOURCES:

A MEDLINE database search (English language, January 1985–April 1997) was performed to identify relevant published articles, including reviews and abstracts; the manufacturer (Hoechst Marion Roussel, Kansas City, MO) provided unpublished data.

STUDY SELECTION:

Pharmacology information was taken from representative original research articles. Eight clinical studies were selected for analysis on the basis of large enrollment, appropriate study design, and publication of results.

DATA EXTRACTION:

All clinical trials, published and unpublished, were reviewed.

DATA SYNTHESIS:

Glimepiride is a sulfonylurea that is pharmacologically distinct from other sulfonylureas because of differences in receptor-binding properties and potentially selective effects on ATP-sensitive K⁺ channels. The pharmacokinetic and pharmacodynamic profile of glimepiride makes it suitable for once-daily dosing. The safety and efficacy of glimepiride have been confirmed in studies involving more than 5000 patients with type 2 diabetes. In one study, once-daily doses of 1–8 mg reduced fasting plasma glucose from baseline by 43–74 mg/dL more than did placebo (p < 0.001), and hemoglobin (Hb) A_1C values decreased by 1.2–1.9% more than with placebo (p < 0.001). Two-thirds of patients achieved tight control (i.e., HbA_1C ≤ 7.2%). Glimepiride was as effective as second-generation sulfonylureas. The most common adverse events were dizziness and headache, but no single adverse event occurred in more than 2% of patients.

CONCLUSIONS:

Glimepiride appears to be a useful option for patients with type 2 diabetes not controlled by diet and exercise and who want to achieve tight glucose control. Glimepiride can be used alone, in combination with other antihyperglycemic agents, or in patients with secondary sulfonylurea failure, as an adjunct to insulin therapy.

Keywords

glimepiride diabetes mellitus

Get full access to this article

View all access options for this article.

References

Davis

Granner

. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman

Limbird

, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:1487–517.

Klimt

Knatterud

Meinert

Prout

, for the University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods, and baseline results. Diabetes 1970;19:747–83.

Meinert

Knatterud

Prout

Klimt

, for the University Group Diabetes Progream. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:789–830.

Kilo

Miller

Williamson

. The Achilles heel of the University Group Diabetes Program. JAMA 1980;243:450–7.

Végh

Papp

. Haemodynamic and other effects of sulphonylurea drugs on the heart. Diabetes Res Clin Pract 1996;31(suppl):S43–53.

Geisen

Végh

Krause

Papp

. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996;28:496–507.

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.

Ohkubo

Kishikawa

Araki

Miyata

Isami

Motoyoshi

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17.

Lebovitz

. Acarbose, an alpha-glucosidase inhibitor, in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Today's Ther Trends 1996;13:207–18.

10.

Bailey

. Biguanides and NIDDM. Diabetes Care 1992;15:755–72.

11.

Tal

. Oral hypoglycemic agents in the treatment of type II diabetes. Am Fam Physician 1993;48:1089–95.

12.

Cook

. The β-cell response to oral hypoglycemic agents. Diabetes Res Clin Pract 1995;28(suppl):S81–9.

13.

Dukes

Philipson

. K⁺ channels: generating excitement in pancreatic β-cells. Diabetes 1996;45:845–53.

14.

Kramer

Müller

Girbig

Gutjahr

Kowalewski

Hartz

Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [³H]glimepiride. Biochim Biophys Acta 1994;1191:278–90.

15.

Bloomgarden

. New and traditional treatment of glycemia in NIDDM. Diabetes Care 1996;19:295–9.

16.

Kramer

Müller

Girbig

Gutjahr

Kowalewski

Hartz

The molecular interaction of sulfonylureas with β-cell ATP-sensitive K⁺-channels. Diabetes Res Clin Pract 1995;28(suppl):S67–80.

17.

Müller

Hartz

Pünter

Ökonomopulos

Kramer

. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994;1191:267–77.

18.

Müller

Satoh

Geisen

. Extrapancreatic effects of sulfonylureas: A comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995;28(suppl):S115–37.

19.

Mμller

Geisen

. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Horm Metab Res 1996;28: 469–87.

20.

Müller

Wied

. The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 1993;42:1852–67.

21.

Müller

Wied

Wetekam

E-M

Crecelius

Unkerbach

Pünter

. Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade. Biochem Pharmacol 1994;48:985–96.

22.

Draeger

Wernicke-Panten

Lomp

H-J

Schuler

Roßkamp

. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): A double-blind comparison with glibenclamide. Horm Metab Res 1996;28:419–25.

23.

Draeger

. Clinical profile of glimepiride. Diabetes Res Clin Pract 1995;28(suppl):S139–46.

24.

Rosenstock

Samols

Muchmore

Schneider

, The Glimepiride Study Group. Glimepiride, a new, once-daily sulfonylurea: A double-blind, placebo-controlled study of NIDDM patients. Diabetes Care 1996;19:1194–9.

25.

Sonnenberg

Garg

Weidler

Dixon

Jaber

Bowen

Short-term comparison of once-versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother 1997;31:671–6.

26.

Robbins

. Glimepiride, a new sulfonylurea for the treatment of non-insulin-dependent diabetes mellitus. Today's Ther Trends 1996;14:181–96.

27.

Krause

Englert

Gogelein

. Adenosine triphosphate-dependent K currents activated by metabolic inhibition in rat ventricular myocytes differ from those elicited by the channel opener rilmakalim. Pflugers Arch 1995;429:625–35.

28.

Bijlstra

Lutterman

Russel

FGM

Thien

Smits

. Interaction of sulfonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1996;39:1083–90.

29.

Prescribing information. Amaryl (glimepiride). Somerville, NJ: Hoechst-Roussel Pharmaceuticals, Inc., October 1995.

30.

Rosenkranz

. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res 1996;28:434–9.

31.

Goldberg

Holvey

Schneider

, The Glimepiride Protocol #201 Study Group. A dose response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996;19:847–56.

32.

Schade

Jovanovic-Peterson

Schneider

. A placebo-controlled dose-titration study of glimepiride in patients with non-insulin-dependent diabetes mellitus (NIDDM). Data on file. Kansas City, MO: Hoechst Marion Roussel, Inc., 1997.

33.

Dills

Schneider

, The Glimepiride/Glyburide Study Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996;28:426–9.

34.

Clark

Goldberg

. Glimepiride dosing and efficacy: Results of placebo-controlled, dose-regimen, and active-controlled trials. In: Whitehouse

Gavin

, eds. Postgraduate medicine special report: therapeutic strategies for managing NIDDM. Minneapolis: McGraw-Hill Healthcare Information Group, June 1997:45–56.

35.

Riddle

. Combined therapy with a sulfonylurea plus evening insulin: Safe, reliable, and becoming routine. Horm Metab Res 1996;28:430–3.

36.

Data on file. Kansas City, MO: Hoechst Marion Roussel, Inc., 1997.

37.

Lebovitz

Pasmantier

. Combination insulin-sulfonylurea therapy. Diabetes Care 1990;13:667–75.

38.

Schneider

Chaikin

. Glimepiride safety. Results of placebo-controlled, dose-regimen, and active-controlled trials. In: Whitehouse

Gavin

, eds. Postgraduate medicine special report: therapeutic strategies for managing NIDDM. Minneapolis: McGraw-Hill Healthcare Information Group, June 1997:33–44.

39.

The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995;18:1510–8.

40.

Hermann

Schersten

Bitzen

P-O

Kjellstrom

Lindgarde

Melander

. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994;17:1100–9.

41.

Cramer

Mattson

Prevey

Scheyer

Ouellette

. How often is medication taken as prescribed? JAMA 1989;261:3273–7.

42.

Scheen

Castillo

Lefèbvre

. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes. Acta Clin Belg 1993;48:259–68.